title: Subchronic oral toxicity study of mixed tocopheryl phosphates in rats.
abstract: Rats were fed diets containing 0%, 1%, 3%, or 5% mixed tocopheryl phosphates for 90 days. No abnormal clinical signs related to treatment appeared. Some statistically significant changes in hematology and clinical chemistry parameters appeared, but the majority were not dose dependent, occurred in only one sex or group, and/or remained within the historical control range for this strain of rat. A statistically significant apparent reduction in blood protein was observed in animals treated with the tocopheryl phosphates, but further investigation showed that the test substance interfered with the protein assay. Repeat analysis using a method unaffected by plasma test substance levels showed no difference in plasma proteins among all groups. Gross necropsy revealed no abnormalities; reduced relative heart and epididymal weights were observed, but were not dose dependent and were considered incidental. Histopathological changes occurred only in the mesenteric lymph node and small intestine. Foreign material in a crystal-like form appeared in macrophages in both organs, and increased in a dose-related fashion. In the lymph node, sinus histiocytosis increased with dose, but the severity was similar between the control and low-dose groups. Foreign-body granulomatous inflammation, associated with Maltese cross birefringence of the crystals was seen in the mid- and high-dose animals, but not the low-dose group. Similarly, the small intestine showed increasing amounts of foreign material and inflammation in the mid- and high-dose but not in the 1% diet. The 1% diet (equivalent to 587 and 643 mg mixed tocopheryl phosphates/kg body weight/day for male and female rats, respectively) was considered the no observed adverse effect level.
authors.affiliation: Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia. robert.gianello@med.monash.edu.au
authors.forename: R
authors.initials: R
authors.lastname: Gianello
authors.forename: W C
authors.initials: WC
authors.lastname: Hall
authors.forename: E
authors.initials: E
authors.lastname: Kennepohl
authors.forename: R
authors.initials: R
authors.lastname: Libinaki
authors.forename: E
authors.initials: E
authors.lastname: Ogru
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002624:Chemistry, Clinical / Q000379:methods; D003460:Crystallization; D004032:Diet; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D004822:Epididymis / Q000187:drug effects / Q000473:pathology; D005260:Female; D006321:Heart / Q000187:drug effects; D006405:Hematology / Q000379:methods; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology; D008297:Male; D008643:Mesentery / Q000187:drug effects / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D019055:No-Observed-Adverse-Effect Level; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D036401:Toxicity Tests, Chronic / Q000379:methods*; D016482:Urinalysis / Q000379:methods; D024502:alpha-Tocopherol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000633:toxicity
chemical_list: C512375:alpha-di-tocopheryl phosphate; C012552:alpha-tocopherol phosphate; D024502:alpha-Tocopherol